Patient characteristics, adverse events, and response to nivolumab treatment

Patient 1Patient 2Patient 3
Prior therapies (no.)665
Stem cell sourceMatched-relatedMatched-relatedHaploidentical and umbilical cord blood
Conditioning regimenReduced intensityReduced intensityReduced intensity
T cell depleted graftYesYesYes
Prior GVHDNoChronic GVHD of gutChronic oral GVHD
Days to relapse following AlloHSCT (no.)1812456389
Localization and size of relapseDiffuse bone and splenic involvementMultifocal adenopathy in mediastinum, retroperitoneum and pelvis. Largest lymph node 2.3 × 1.5 cm in mediastinumMultifocal adenopathy in neck, chest, abdomen and pelvis. Largest lymph node 4.2 × 1.8 cm in right axilla
Prior DLINoYesNo
Immune-related adverse eventsGrade 2 KeratoconjunctivitisGrade 3 Inflammatory polyarthritis and grade 2 keratoconjunctivitisGrade 1 Rash
Response to nivolumabPartial responsePartial responsePartial response
Duration of response6 Months+10 Months+14 Months+
Donor CD3+ chimerism before and after treatment18 to 49%Not availableNot available